NCT05736952 2023-05-11
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT05481775 2022-11-21
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Withdrawn
NCT04947371 2021-07-01
Adjuvant Therapy With Anlotinib for HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn